All entries on BioNTech across all areas, newest first. tag:eurotrack.ai,2026:en:en/companies/biontech 2026-05-05T06:00:00Z Eurotrack tag:eurotrack.ai,2026:0d4ee9d1:en 2026-05-05T06:00:00Z

BioNTech is ending Covid vaccine production in Germany and cutting up to 1,860 jobs (around 22 percent). Those affected include Marburg (around 540), Idar-Oberstein (around 440) and around 820 jobs at the acquired company CureVac; expected savings of up to €500 mn per year from 2029. Update (28.09.2026): BioNTech found no buyers for its three German plants; they will close in stages – Tübingen at the end of 2027, Marburg in early 2028, Idar-Oberstein at the end of 2028 – affecting about 1,800 employees according to the company (ZDFheute, 28.09.2026). — Sources: https://www.onvista.de/news/2026/05-05-biontech-schliesst-deutsche-werke-und-streicht-1860-stellen-0-20-26508128 · https://www.zdfheute.de/wirtschaft/unternehmen/biontech-marburg-idar-oberstein-tuebingen-schliessung-100.html

tag:eurotrack.ai,2026:80d9b86d:en 2026-05-05T06:00:00Z

As part of the group restructuring, BioNTech is closing its Marburg production plant by the end of 2027; around 540 jobs are being cut. The background is the sharply declined demand for coronavirus vaccines. Cross-reference: the roughly 540 jobs are included in the up to 1,860 jobs of the group restructuring announced the same day (layoffs entry of 5 May 2026); the figure is carried there and set to null here to avoid double counting. Update (28.09.2026): The search for buyers failed; BioNTech confirmed the closure and now gives early 2028 as the end date for Marburg (Tübingen end of 2027, Idar-Oberstein end of 2028; about 1,800 employees in total), citing a difficult market and investment climate (ZDFheute, 28.09.2026). — Sources: https://www.wiwo.de/unternehmen/industrie/biontech-schliesst-standorte-und-baut-1860-stellen-ab/100222527.html · https://www.zdfheute.de/wirtschaft/unternehmen/biontech-marburg-idar-oberstein-tuebingen-schliessung-100.html

tag:eurotrack.ai,2026:281be517:en 2026-05-05T06:00:00Z

The Idar-Oberstein plant will also be closed by the end of 2027, with around 440 jobs affected. In Germany, besides the headquarters in Mainz, only the office locations in Berlin and Munich will remain. Cross-reference: the roughly 440 jobs are included in the up to 1,860 jobs of the group restructuring announced the same day (layoffs entry of 5 May 2026); the figure is carried there and set to null here to avoid double counting. Update (28.09.2026): The search for buyers failed; BioNTech confirmed the closure and now gives the end of 2028 as the end date for Idar-Oberstein (Tübingen end of 2027, Marburg early 2028; about 1,800 employees in total), citing a difficult market and investment climate (ZDFheute, 28.09.2026). — Sources: https://www.wiwo.de/unternehmen/industrie/biontech-schliesst-standorte-und-baut-1860-stellen-ab/100222527.html · https://www.zdfheute.de/wirtschaft/unternehmen/biontech-marburg-idar-oberstein-tuebingen-schliessung-100.html

tag:eurotrack.ai,2026:27b16f63:en 2025-11-25T06:00:00Z

CureVac shareholders voted with over 99% in favour of the takeover by BioNTech. The exchange offer runs until 3 December 2025, with CureVac shares being exchanged for BioNTech ADS. Antitrust approval is in place. CureVac will be delisted and integrated into BioNTech. The open legal dispute with Pfizer/BioNTech was suspended. Update (18.12.2025): BioNTech closed its acquisition of CureVac on 18.12.2025; the compulsory acquisition of the remaining shares and the end of trading in CureVac shares were scheduled for January 2026 as part of the post-offer reorganisation (BioNTech press release via BioSpace, 18.12.2025). — Source: https://www.msn.com/de-de/finanzen/top-stories/fusion-mit-biontech-curevac-aktion%C3%A4re-haben-entschieden-so-reagieren-die-aktien/ar-AA1RaVjE

tag:eurotrack.ai,2026:59349f3f:en 2025-10-22T06:00:00Z

BioNTech is launching a public exchange offer for the full takeover of CureVac; the all-stock deal values CureVac at around $1.25 billion. Update (6 January 2026): The takeover is complete — after the exchange offer, BioNTech took over all remaining CureVac shares through a post-offer reorganisation and is now the sole owner; Nasdaq trading was suspended on 6 January 2026 and the delisting took effect on 16 January 2026 (Panabee, 6 January 2026). — Source: https://www.biontech.com/int/en/home/mediaroom/news/press-releases/2025/10/biontech-commences-public-exchange-offer-all-outstanding-shares.html